Visterra, Inc. is a biotechnology company based in Waltham, MA, dedicated to bringing better biologics to life. With a strong leadership team and a focus on innovative research, Visterra aims to develop groundbreaking therapies for various medical conditions.
Through their comprehensive approach and extensive pipeline of programs, including VIS649 Sibeprenlimab, VIS171, and VIS513, Visterra is committed to advancing the field of biotechnology and improving patient outcomes. Their dedication to clinical trials, particularly in the area of IgA Nephropathy, showcases their commitment to finding effective treatments for challenging diseases.
Generated from the website